Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

387 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel designs and end points for phase II clinical trials.
Adjei AA, Christian M, Ivy P. Adjei AA, et al. Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. Pitot HC, et al. Clin Cancer Res. 2002 Mar;8(3):712-7. Clin Cancer Res. 2002. PMID: 11895900 Clinical Trial.
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Adjei AA, et al. J Clin Oncol. 2002 Mar 15;20(6):1683-91. doi: 10.1200/JCO.2002.20.6.1683. J Clin Oncol. 2002. PMID: 11896120 Clinical Trial.
Farnesyltransferase inhibitors in breast cancer therapy.
Dy GK, Adjei AA. Dy GK, et al. Cancer Invest. 2002;20 Suppl 2:30-7. doi: 10.1081/cnv-120014884. Cancer Invest. 2002. PMID: 12442347 Review.
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. Adjei AA, et al. Clin Cancer Res. 2003 Jan;9(1):115-23. Clin Cancer Res. 2003. PMID: 12538459 Clinical Trial.
Farnesyltransferase inhibitors.
Adjei AA. Adjei AA. Cancer Chemother Biol Response Modif. 2002;20:151-67. Cancer Chemother Biol Response Modif. 2002. PMID: 12703204 Review. No abstract available.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Adjei AA, et al. J Clin Oncol. 2003 May 1;21(9):1760-6. doi: 10.1200/JCO.2003.09.075. J Clin Oncol. 2003. PMID: 12721252 Clinical Trial.
Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA. Adjei AA. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. doi: 10.1586/14737140.3.2.145. Expert Rev Anticancer Ther. 2003. PMID: 12722874 Review.
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. Scott AM, et al. Clin Cancer Res. 2003 May;9(5):1639-47. Clin Cancer Res. 2003. PMID: 12738716 Clinical Trial.
387 results
Jump to page
Feedback